Team
Our highly experienced and diverse global organization is a key strength and differentiator with team member experience extending across science, medicine, commercial, operations, and strategy
Founder and Managing Partner
James Huang
An industry veteran with over 30 years of biotech experience previously with KPCB and Vivo Ventures
See full bio
Founder and Managing Partner
James Huang
- James is an industry veteran with over 30 years of biotech experience. He is a successful entrepreneur and investor dedicated to investing in disruptive innovation and supporting entrepreneurs to build global companies that will transform the lives of patients around the world.
- He founded Panacea Venture to focus on investments in global innovative early and growth stage healthcare and life sciences companies.
- James was previously Managing Partner of Kleiner Perkins (KPCB) China and Managing Partner at Vivo Ventures.
- Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. He also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson).
- James is currently a director at Kindstar Globalgene Technology Inc. (9960.HK), Connect Biopharma Holdings Limited (Nasdaq: CNTB) and several private companies.
- James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.
Partners
Partners make up the core of the investing team and collectively have more than 100 years of VC experience
Andrew Aherrera
Partner
Partner
Andrew Aherrera
- Previously Portfolio Manager of Ample Plus, a healthcare dedicated crossover investment fund
- Prior role at RA Capital, covering CNS, Hepatology, and Oncology
- MD/MBA, Tufts University School of Medicine
Cheryl Bao
Chief Legal Officer
Chief Legal Officer
Cheryl Bao
- Previously attorney at Ropes & Gray LLP
- LLM, University of Pennsylvania; LLM/LLB, Shanghai University of International Business and Economics
Benjamin Chen
Scientific Partner
Scientific Partner
Benjamin Chen
- Previously CEO of ImaginAb, CEO and Chairman of Immune Targeting Systems, and Managing Director at Burrill & Company
- PhD in Immunology, University of Wisconsin; Postdoc Cancer immunology, Stanford University
Arthur Chen
Partner
Partner
Arthur Chen
- Founding, Managing Partner, BE Health; CIO, Show Chwan Health Care System
- Specially Appointed Professor, Tohoku University; Global Faculty Fellow, Stanford Biodesign
- EMBA (Columbia, LBS, HKU); MS Biomedical Informatics TMU; MS Electrical Engineering NTU
Michelle Chung
Venture Partner
Venture Partner
Michelle Chung
- Previously VP Marketing at Braeburn
- Held senior leadership roles at GlaxoSmithKline, Teva and Anesiva
- BA in communication, Villanova
Delia Ding
Chief Financial Officer
Chief Financial Officer
Delia Ding
- Previously Finance Director at KPCB China
- BA Accounting, Tongji University
Nancy Donahue
Venture Partner
Venture Partner
Nancy Donahue
- Previously Senior VP of Sales and Marketing at Anesiva;
- Held senior leadership roles at Braeburn, Teva and GlaxoSmithKline
- BS Food marketing, Saint Joseph’s University
Carl Firth
Partner
Partner
Carl Firth
- Previously CEO and Founder ASLAN Pharmaceuticals
- Prior roles Head of Asia Healthcare at Bank of America Merrill Lynch, Regional BD Director AsiaPac at AstraZeneca
- Assoc Professor Duke-NUS Medical School; PhD, MA Molecular Biology, Trinity College, Cambridge; MBA, London Business School
Wayne Huang
Venture Partner
Venture Partner
Wayne Huang
- Chief Central Superintendent, Show Chwan Healthcare System; Director, IRCAD Taiwan/AITS (Asian Institute of TeleSurgery)
- Partner, BE Health
- Founding member, Asia Society of Medical Innovation and Technology
- MD, Tulane University School of Medicine; PhD, Tokyo Women's Medical University; MPH, Tulane University, Public Health
Mathias Hukkelhoven, PhD
Venture Partner
Venture Partner
Mathias Hukkelhoven, PhD
- Previously SVP, Global Regulatory, Safety & Biometrics at BMS; Novartis, Hoffmann La Roche
- Formerly: Chairman of the Regulatory Affairs Coordinating Committee at PhRMA
- Member of the Board of Directors of Centessa (NASDAQ: CNTA) and Compugen (NASDAQ: CGGEN)
- B.S. and Ph.D. in Biology and Biochemistry University of Nijmegen, the Netherlands
Rosemary Mazanet
Venture Partner
Venture Partner
Rosemary Mazanet
- Previously at Oracle Partners, Apelles, Argenis, Amgen
- Emeritus Trustee at the University of Pennsylvania Health System; Chair, Executive Advisory Board for the Wharton Leonard Davis Institute
- MD PhD University of Pennsylvania
Andrew Ng
Partner
Partner
Andrew Ng
- Head of Healthcare Investment at VMS Group
- Previously Head of China Healthcare, Equity Research, Barclays Capita
- MBA from INSEAD; BS, Meng, Engineering and Operations Research, Cornell
Eric Sun
Head of Investor Relations
Head of Investor Relations
Eric Sun
- 20 years of experience in Private Markets, both as investor and fundraiser
- Previously, Principal at Blue Owl Capital; Director at Credit Suisse PFG
- Prior investor: Managing Director at PingAn Group, Head of Private Markets at Nanshan Life, Investment manager at Schroeder Adveq
- BS in Business Management, Indiana University
Winson Tang
Scientific Partner
Scientific Partner
Winson Tang
- Recipient of FDA/CBER Scientific Achievement Award for Regulatory Science; Reviewer in Gene and Cell Therapy, CBER FDA 2017-2021
- Prior roles at Sangamo, Amgen Amsterdam Molecular Therapeutics, Pacific Capital Group
- MD, Albert Einstein College of Medicine of Yeshiva University
Jeffry Wu
Partner
Partner
Jeffry Wu
- Previously, partner at 7G Bioventures; Head of Healthcare investments; AGIC Capital and Milestone Capital; Director, JJDC
- PhD Neuroscience, Columbia University; B.S. Biological Sciences, University of Science and Technology of China
Fay Xing
Scientific Partner
Scientific Partner
Fay Xing
- Previously, partner at 6 Dimensions Capital/WuXi Healthcare Ventures; Co-head/managing director of pharma/biotech at CBC group; Principal at Decheng capital
- BA in Biochemistry, Columbia; MD, Stanford; MBA, Harvard
Debra Yu
Chief Operating Officer
Chief Operating Officer
Debra Yu
- Previously, President and Chief Strategy Officer of LianBio; Managing Director Cross-border Investment Banking at China Renaissance
- Prior roles at Pfizer, Bay City Capital and Delphi Ventures
- MD Harvard Medical School; BA Molecular Biology, Princeton
Nikki Zhang
Partner
Partner
Nikki Zhang
- Previously Director at KPCB
- Prior roles at Zimmer Biomet and Hutchison MediPharma
- MBA, Duke; M.A. in Biotechnology, Columbia; BS Biochemistry, University of Texas at Austin
Pei Zhou
Partner
Partner
Pei Zhou
- Previously Partner at Kairos, InnoPinnacle and Pagoda Capital
- PhD Dartmouth; MS/BS Biomedical Engineering Tianjing University